IMAX Corporation (NASDAQ: IMAX) is a recent featured stock from Jim Oberweis, Jr. Here, the money manager and editor of The Oberweis Report explains why his clients own 600,000 shares.

"IMAX specializes in motion picture technologies and large-format film presentations. IMAX designs and manufactures large-format digital and film-based theater systems.

"The company sells or leases such systems to its customers, and converts two-dimensional '2D' and three-dimensional '3D' Hollywood feature films for exhibition on such systems around the world.

"We believe that the recent relative strength of tech stocks is the start of a longer term trend, not merely a flash in the pan," says Jim Oberweis and Dave Covas.

In The Oberweis Report, the money managers and small cap advisors explain, "Our confidence stems from the emergence of the next Killer Apps, which drive technology cycles because they change how we live our lives." Here, they make a case for technology and offer a trio of small cap favorites.

"During the 1980's and early 1990's, the personal computer was the Killer App. During the late 1990's, it was the Internet. During this decade – zilch. Until now. The next Killer Apps – video-on-demand and ubiquitous high-speed wireless connectivity – are coming.

"The Chinese Dragon strikes again," says small cap expert Jim Oberweis, Jr., adding, "So far in 2009, the MSCI China Index is up 30% and our Oberweis China Opportunities Fund (OBCHX) has gained 62%."

In his The Oberweis Report, he says, "China will be a great place to invest over the medium-to-long term, even if unpredictable in the short term."

Here, the advisor and money manager reveals four stocks that he considers "some of the most interesting Chinese ADRs to buy now: E-House (NYSE: EJ), Asia Info Holdings (NASDAQ: ASIA), New Oriental Education (NYSE: EDU), and Longtop Financial (NYSE: LFT).

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Investors who can find the diamonds in the rough stand to profit handsomely," says small cap growth stock expert and money manager Jim Oberweis, Jr.

In his The Oberweis Report, he suggests Green Mountain Coffee Roasters (NASDAQ: GMCR) is one stock that fits the bill. As his top pick for 2009, he looks to the maker of specialty coffees and single-cup home brewing systems.

"There is no question that any company whose growth depends on selling goods to the U.S. consumer, especially non-essential goods, would seem risky at the present moment. But stock prices for most retail companies are already down in the dumps and reflect significantly reduced expectations.

"We've been looking for growth companies that won't be as badly affected as many folks believe. Green Mountain Coffee Roasters is one stock that fits the bill.